Physician profile
Raphael E Perez
NPI 1164545992
$7,955.62
in general payments reported to CMS, 2019-2025
28 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $523 · 2021: $361 · 2022: $1,115 · 2023: $1,208 · 2024: $1,462 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,708 · Entertainment: $62.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,707.61 |
| Entertainment | $62.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,778.55 | 2023-2025 | Miebo, Xiidra, Infuse |
| Allergan, INC. | $791.75 | 2019-2022 | |
| Coopervision INC. | $495.99 | 2019-2024 | Clariti Contact Lens, Biofinity Contact Lens |
| Oyster Point Pharma, INC. | $456.03 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $444.43 | 2019-2022 | |
| Alcon Vision LLC | $412.57 | 2023-2024 | Simbrinza, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $356.01 | 2024-2025 | Xdemvy |
| Genzyme Corporation | $337.33 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $334.96 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $324.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $261.70 | 2019-2023 | |
| Dompe US, INC. | $261.52 | 2024-2025 | Oxervate |
| Shire North American Group INC | $235.67 | 2019 | |
| Optos, INC. | $159.10 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Eyevance Pharmaceuticals LLC | $139.18 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $135.51 | 2023 | Lipiflow System Activator (Disposable) |
| Abbvie INC. | $125.00 | 2023 | |
| Harrow Eye, LLC | $124.99 | 2025 | Vevye |
| Sight Sciences, INC. | $123.57 | 2022 | |
| Maculogix, INC. | $114.61 | 2020 | |
| Biotissue Holdings INC. | $106.82 | 2023 | |
| Abb Con-Cise Optical Group LLC | $103.86 | 2019 | |
| Rxsight INC | $82.55 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Optovue, INC. | $79.79 | 2019 | |
| Topcon Healthcare, INC. | $79.26 | 2022 | |
| Visionix USA, INC | $46.88 | 2022 | |
| Glaukos Corporation | $27.78 | 2019 | |
| Aerie Pharmaceuticals, INC. | $15.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.